{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:27Z","timestamp":1790912487020,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Vaccines Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dengue is an increasing threat to global health. This exploratory analysis evaluated the immunogenicity, safety, and vaccine efficacy (VE) of a live-attenuated tetravalent dengue vaccine (TAK-003) in participants enrolled in the phase 3 DEN-301 trial (NCT02747927), stratified by baseline age (4\u20135 years, 6\u201311 years, or 12\u201316 years).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were randomized 2:1 to receive 2 doses of TAK-003, administered 3 months apart, or placebo. Dengue serostatus was evaluated at enrolment. VE against virologically confirmed dengue (VCD) and hospitalized VCD; immunogenicity (geometric mean titers [GMTs]); and safety were evaluated per age group through \u223c4 years postvaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>VE against VCD across serotypes was 43.5% (95% confidence interval [CI]: 25.3%, 57.3%) for 4\u20135 year-olds; 63.5% (95% CI: 56.9%, 69.1%) for 6\u201311 year-olds, and 67.7% (95% CI: 57.8%, 75.2%) for 12\u201316 year-olds. VE against hospitalized VCD was 63.8% (95% CI: 21.1%, 83.4%), 85.1% (95% CI: 77.1%, 90.3%), and 89.7% (95% CI: 77.9%, 95.2%), for the 3 age groups, respectively. GMTs remained elevated against all 4 serotypes for \u223c4 years postvaccination, with no evident differences across age groups. No clear differences in safety by age were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This exploratory analysis shows TAK-003 was efficacious in dengue prevention across age groups in children and adolescents 4\u201316 years of age living in dengue endemic areas. Relatively lower VE in 4\u20135 year-olds was potentially confounded by causative serotype distribution, small sample size, and VE by serotype, and should be considered in benefit-risk evaluations in this age group.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae369","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T16:00:56Z","timestamp":1720800056000},"page":"199-206","source":"Crossref","is-referenced-by-count":17,"title":["Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group"],"prefix":"10.1093","volume":"80","author":[{"given":"Charissa","family":"Borja-Tabora","sequence":"first","affiliation":[{"name":"Clinical Research Division, Research Institute for Tropical Medicine , Muntinlupa ,","place":["Philippines"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LakKumar","family":"Fernando","sequence":"additional","affiliation":[{"name":"Centre for Clinical Management of Dengue & Dengue Haemorrhagic Fever, Negombo General Hospital , Negombo ,","place":["Sri Lanka"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Lopez Medina","sequence":"additional","affiliation":[{"name":"Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica CEIP, Universidad del Valle and Cl\u00ednica Imbanaco Grupo Quironsalud , Cali ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Reynales","sequence":"additional","affiliation":[{"name":"Centro de Atenci\u00f3n e Investigaci\u00f3n M\u00e9dica, CAIMED , Bogot\u00e1 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rivera","sequence":"additional","affiliation":[{"name":"Hospital Maternidad Nuestra Senora de Altagracia , Santo Domingo ,","place":["Dominican Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Saez-Llorens","sequence":"additional","affiliation":[{"name":"Hospital del Ni\u00f1o Dr. Jos\u00e9 Ren\u00e1n Esquivel, Sistema Nacional de Investigaci\u00f3n at SENACYT, Centro de Vacunaci\u00f3n Internacional (Cevaxin) , Panama City ,","place":["Panama"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukiat","family":"Sirivichayakul","sequence":"additional","affiliation":[{"name":"Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Yu","sequence":"additional","affiliation":[{"name":"Pediatrics, De La Salle Medical and Health Sciences Institute , Dasmari\u00f1as ,","place":["Philippines"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Folschweiller","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley J","family":"Moss","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rauscher","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-8647","authenticated-orcid":false,"given":"Vianney","family":"Tricou","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibadas","family":"Biswal","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"2025020710485202300_ciae369-B1","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2542-5196(21)00132-7","article-title":"Projecting the risk of mosquito-borne diseases in a warmer and more populated world: a multi-model, multi-scenario intercomparison modelling study","volume":"5","author":"Col\u00f3n-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Planet Health"},{"key":"2025020710485202300_ciae369-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12992-021-00793-2","article-title":"Charting the evidence for climate change impacts on the global spread of malaria and dengue and adaptive responses: a scoping review of reviews","volume":"18","author":"Kulkarni","year":"2022","journal-title":"Glob Health"},{"key":"2025020710485202300_ciae369-B3","doi-asserted-by":"crossref","first-page":"e0009631","DOI":"10.1371\/journal.pntd.0009631","article-title":"The role of urbanisation in the spread of Aedes mosquitoes and the diseases they transmit: a systematic review","volume":"15","author":"Kolimenakis","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2025020710485202300_ciae369-B4","author":"World Health Organization"},{"key":"2025020710485202300_ciae369-B5","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1038\/s41467-021-25421-w","article-title":"Suppressing mosquito populations with precision guided sterile males","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"2025020710485202300_ciae369-B6","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1056\/NEJMoa2030243","article-title":"Efficacy of Wolbachia-infected mosquito deployments for the control of dengue","volume":"384","author":"Utarini","year":"2021","journal-title":"N Engl J Med"},{"key":"2025020710485202300_ciae369-B7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fcimb.2017.00336","article-title":"Prevention and control strategies to counter dengue virus infection","volume":"7","author":"Rather","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"2025020710485202300_ciae369-B8","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"Dengue vaccine: WHO position paper, September 2018\u2014recommendations","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"2025020710485202300_ciae369-B9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"2025020710485202300_ciae369-B10","doi-asserted-by":"crossref","first-page":"e1350","DOI":"10.1093\/cid\/ciac418","article-title":"Clinical safety experience of TAK-003 for dengue fever: a new tetravalent live attenuated vaccine candidate","volume":"76","author":"Patel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025020710485202300_ciae369-B11","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/infdis\/jiaa406","article-title":"Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: a randomized, placebo-controlled, phase 2 study","volume":"225","author":"Sirivichayakul","year":"2022","journal-title":"J Infect Dis"},{"key":"2025020710485202300_ciae369-B12","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"2025020710485202300_ciae369-B13","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"2025020710485202300_ciae369-B14","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.26633\/RPSP.2021.67","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine in dengue-na\u00efve adolescents in Mexico City","volume":"45","author":"Biswal","year":"2021","journal-title":"Rev Panam Salud Publica"},{"key":"2025020710485202300_ciae369-B15","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of Takeda's dengue vaccine (TAK 003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2025020710485202300_ciae369-B16","first-page":"602","article-title":"Mapping dengue in children in a Colombian Caribbean Region: clinical and epidemiological analysis of more than 3500 cases","volume":"30","author":"Ricardo-Rivera","year":"2022","journal-title":"Infez Med"},{"key":"2025020710485202300_ciae369-B17","doi-asserted-by":"crossref","first-page":"e0010333","DOI":"10.1371\/journal.pntd.0010333","article-title":"Incidence of lab-confirmed dengue fever in a pediatric cohort in Delhi, India","volume":"16","author":"Sinha","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2025020710485202300_ciae369-B18","doi-asserted-by":"crossref","first-page":"e0010966","DOI":"10.1371\/journal.pntd.0010966","article-title":"Epidemiology and costs of dengue in Thailand: a systematic literature review","volume":"16","author":"Thisyakorn","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2025020710485202300_ciae369-B19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14760584.2018.1546581","article-title":"Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine","volume":"17","author":"God\u00f3i","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2025020710485202300_ciae369-B20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3201\/eid2604.190435","article-title":"Severe dengue epidemic, Sri Lanka, 2017","volume":"26","author":"Tissera","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2025020710485202300_ciae369-B21","author":"Ministry of Health Singapore"},{"key":"2025020710485202300_ciae369-B22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa1503877","article-title":"Symptomatic dengue in children in 10 Asian and Latin American countries","volume":"374","author":"L'Azou","year":"2016","journal-title":"N Engl J Med"},{"key":"2025020710485202300_ciae369-B23","doi-asserted-by":"crossref","first-page":"108510","DOI":"10.1016\/j.clim.2020.108510","article-title":"Development of child immunity in the context of COVID-19 pandemic","volume":"217","author":"Kloc","year":"2020","journal-title":"Clin Immunol"},{"key":"2025020710485202300_ciae369-B24","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"2025020710485202300_ciae369-B25","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020710485202300_ciae369-B26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J Infect Dis"},{"key":"2025020710485202300_ciae369-B27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025020710485202300_ciae369-B28","doi-asserted-by":"crossref","first-page":"e0011124","DOI":"10.1371\/journal.pntd.0011124","article-title":"Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: a phase 3 randomized, controlled study","volume":"17","author":"Tricou","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"2025020710485202300_ciae369-B29","doi-asserted-by":"crossref","first-page":"e0004262","DOI":"10.1371\/journal.pntd.0004262","article-title":"Epidemiology of infant dengue cases illuminates serotype-specificity in the interaction between immunity and disease, and changes in transmission dynamics","volume":"9","author":"Clapham","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"2025020710485202300_ciae369-B30","author":"World Health Organization"},{"key":"2025020710485202300_ciae369-B31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"key":"2025020710485202300_ciae369-B32","doi-asserted-by":"crossref","first-page":"2254964","DOI":"10.1080\/21645515.2023.2254964","article-title":"An open-label, phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life","volume":"19","author":"Patel","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2025020710485202300_ciae369-B33","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1016\/j.vaccine.2023.09.049","article-title":"Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): a randomized placebo-controlled trial in US adults","volume":"41","author":"Tricou","year":"2023","journal-title":"Vaccine"},{"key":"2025020710485202300_ciae369-B34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-023-00670-6","article-title":"Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults","volume":"8","author":"LeFevre","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025020710485202300_ciae369-B35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1473-3099(22)00025-1","article-title":"Measuring the effects of COVID-19-related disruption on dengue transmission in Southeast Asia and Latin America: a statistical modelling study","volume":"22","author":"Chen","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025020710485202300_ciae369-B36","doi-asserted-by":"crossref","first-page":"e0001558","DOI":"10.1371\/journal.pgph.0001558","article-title":"Dengue amid COVID-19 pandemic","volume":"3","author":"Tangsathapornpong","year":"2023","journal-title":"PLoS Glob Public Health"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae369\/60683412\/ciae369.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/199\/60683412\/ciae369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/199\/60683412\/ciae369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T10:49:14Z","timestamp":1738925354000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/1\/199\/7712860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,12]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae369","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,7,12]]}}}